BMC Cancer

Section Editors

Paolo Bruzzi, National Cancer Research Institute
Carlos Caldas, Cambridge Research Institute
Ian Cree, Warwick Medical School, Coventry
Shoukat Dedhar, British Columbia Cancer Agency
John A Hartley, University College London
Manami Inoue, University of Tokyo
Mark McKeage, University of Auckland
Christophe Nicot, Kansas University Medical Center
Stephen P Povoski, The Ohio State University
Dirk Vordermark, Martin Luther University Halle-Wittenberg

Executive Editor

Dafne Solera, BioMed Central

Editorial Board | Editorial Team | Instructions for authors | FAQ

Articles

There has been an error retrieving the data. Please try again.

Exome profiling of ovarian carcinoma

Whole-exome sequencing of primary, metastatic and recurrent ovarian carcinoma from a single BRCA1-positive patient is a powerful method to detect subsequent somatic mutations and can provide information about the molecular evolution of BRCA1-driven ovarian cancer.

BMC Cancer 2013, 13:146
PRL-3 in ovarian cancer tumorigenicity

The protein tyrosine phosphatase PRL-3 (Phosphatase of Regenerating Liver-3) is highly expressed in human ovarian cancer patient samples and may promote cancer cell migration, invasion and metastasis via inhibition of c-fos transcriptional regulation of integrin alpha2 signaling.

BMC Cancer 2013, 13:80
Childbirth in young adult cancer survivors

Recurrence-free female young adult survivors of non-gynecologic malignancies are less likely than controls to give birth after diagnosis, and the overall modest effect is influenced by pre-diagnosis childbirth and malignancy type.

BMC Cancer 2013, 13:30
View more articles

RSS

Comments

No such thing as homeopathy?

Comment on: Rostock et al. BMC Cancer 2013, 11:19
Contrasting results from new study...?

Comment on: Rostock et al. BMC Cancer 2013, 11:19
Without homeopathic remedies, is care 'homeopathic'?

Comment on: Rostock et al. BMC Cancer 2013, 11:19

Hot topic

Profiling of normal and malignant breast tissue show CD44high/CD24low phenotype as a predominant stem/progenitor marker when used in combination with Ep-CAM/CD49f markers

Ghebeh H, Sleiman GM, Manogaran PS, Al-Mazrou A, Barhoush E, Al-Mohanna FH, Tulbah A, Al-Faqeeh K et al.

BMC Cancer 2013, 13:289

RSS

News from the web

19 June 2013: Polyp growth identifies colorectal cancer

17 June 2013: Early motherhood reduces kidney cancer risk

10 June 2013: Transperineal prostate biopsy shows core–complication connection

Scope

BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.

It is journal policy to publish work deemed by peer reviewers to be a coherent and sound addition to scientific knowledge and to put less emphasis on interest levels, provided that the research constitutes a useful contribution to the field.

Join the Editorial Board!

Are you interested in becoming an Editorial Board member for BMC Cancer and helping to maintain the editorial standards and ethos of this growing journal? To volunteer as an Associate Editor, please simply contact us at bmccancer@biomedcentral.com, enclosing a summary of your research interests and relevant expertise. We look forward to hearing from you.

Latest review

Review

Christudas Morais, David W Johnson, David A Vesey, and Glenda C Gobe1

BMC Cancer 2013, 13:14 (10 January 2013)

Abstract | Full text | PDF | PubMed

Section Editor's profile

Mark McKeage is a medical oncologist and associate professor in the department of pharmacology and clinical pharmacology and co-director of the Auckland Cancer Society Research Centre at the university of Auckland, New Zealand. His current research focuses on how membrane transporters determine response and handling of platinum-based anticancer drugs. In addition, he leads a programme of phase I oncology trials at his centre.

"BMC Cancer is the leading Open Access international journal in the field of oncology. By publishing over 500 articles per year, BMC Cancer offers rapid dissemination of the most recent information of interest to the broad oncology science community."

Prof McKeage is the Section Editor of the Clinical oncology- medical oncology and pharmacology section of BMC Cancer.

RSS